{"id":"https://genegraph.clinicalgenome.org/r/da1213da-0170-4955-9200-cfc058b0bd56v1.1","type":"EvidenceStrengthAssertion","dc:description":"","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/da1213da-0170-4955-9200-cfc058b0bd56","GCISnapshot":"https://genegraph.clinicalgenome.org/r/2f6d71c6-6595-49bf-a50e-fce726b22088","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/2f6d71c6-6595-49bf-a50e-fce726b22088_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10016","date":"2021-01-28T20:17:52.314Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/2f6d71c6-6595-49bf-a50e-fce726b22088_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10016","date":"2018-10-05T16:00:00.000Z","role":"Approver"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2f6d71c6-6595-49bf-a50e-fce726b22088_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2f6d71c6-6595-49bf-a50e-fce726b22088_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cb1a6d5f-a311-4634-8542-1d010f5efd4d_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Glucksmann- Family B","estimatedLodScore":4.82,"family":{"id":"https://genegraph.clinicalgenome.org/r/cb1a6d5f-a311-4634-8542-1d010f5efd4d","type":"Family","rdfs:label":"Glucksmann- Family B","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/b6adbb0a-e676-44bc-aa3b-442ccee4f0f8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Glucksmann Family B-IV:1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":37,"detectionMethod":"Linkage analysis was performed across this family and 8 others) to determine the region responsible for MODY3. BAC and PAC constructioni was used to narrow the region of interest on chromosome 12q (markers D12S86 and D12S342). SSCP assays and sequence analysis were performed to identify the mutations in known and novel transcript. An additional 15 transcripts in the region were sequenced to negate their association with MODY3 disease.","phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypes":"obo:HP_0004904","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/dae43e13-96f3-4f5d-940f-517f49d801cb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","allele":{"id":"https://genegraph.clinicalgenome.org/r/4a67f227-df43-4ab7-9119-700e69cf67be","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000012.12:g.120979088T>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA386954873"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypeNegativeAlleleNegative":14,"phenotypePositiveAllelePositive":16,"phenotypes":"obo:HP_0004904","proband":{"id":"https://genegraph.clinicalgenome.org/r/b6adbb0a-e676-44bc-aa3b-442ccee4f0f8"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/4ce541c2-6d44-4c63-aef8-956666d18cc5_proband_segregation","type":"FamilyCosegregation","dc:description":"This family does not meet the minimum requirement of 4 segregations to count per the SOP.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Glucksmann Family H","estimatedLodScore":0.9,"family":{"id":"https://genegraph.clinicalgenome.org/r/4ce541c2-6d44-4c63-aef8-956666d18cc5","type":"Family","rdfs:label":"Glucksmann Family H","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/97b4e6d2-d0ae-4ad9-9730-e51d9180d698","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Gluskmann Family H-II:1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":20,"detectionMethod":"Linkage analysis was performed across this family and 8 others) to determine the region responsible for MODY3. BAC and PAC constructioni was used to narrow the region of interest on chromosome 12q (markers D12S86 and D12S342). SSCP assays and sequence analysis were performed to identify the mutations in known and novel transcript. An additional 15 transcripts in the region were sequenced to negate their association with MODY3 disease.","phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypes":"obo:HP_0004904","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/31fd1ac3-398f-4d4d-8b2f-138f7a8ef370_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","allele":{"id":"https://genegraph.clinicalgenome.org/r/970ad361-fd5c-4ac8-bde0-de66b2f7d2ac","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000545.6(HNF1A):c.872dupC (p.Gly292Argfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/14927"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":4,"phenotypes":"obo:HP_0004904","proband":{"id":"https://genegraph.clinicalgenome.org/r/97b4e6d2-d0ae-4ad9-9730-e51d9180d698"}},{"id":"https://genegraph.clinicalgenome.org/r/7e199697-8911-45ff-809e-081b1574c001_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","rdfs:label":"Family H","estimatedLodScore":2.11,"family":{"id":"https://genegraph.clinicalgenome.org/r/7e199697-8911-45ff-809e-081b1574c001","type":"Family","rdfs:label":"Family H","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/fee0c6ef-c9c5-4b2e-a0dc-826d920114a5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","rdfs:label":"Family H-III:2","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Linkage analysis using BAC, YAC, and PAC in the region of HNF1A on chromosome 12. Tested genes known in this region, exon trapping, and cDNA selection from pancreatic islets. Sequenced the 14 protein encoding genes in the region in addition to HNF1A. Sequenced all 10 exons in HNF1A.","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0004904","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/4f3e8aa2-1a0a-466c-b3ec-7c51dbf9bda2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","allele":{"id":"https://genegraph.clinicalgenome.org/r/bd91bdcd-38b9-4da8-8868-94bf86a26d04","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000012.12:g.120988898G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA6831746"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":3,"phenotypePositiveAllelePositive":7,"phenotypes":"obo:HP_0004904","proband":{"id":"https://genegraph.clinicalgenome.org/r/fee0c6ef-c9c5-4b2e-a0dc-826d920114a5"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/6b402271-41f5-4b9e-90b9-399c082497fc_family_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","rdfs:label":"Family GK","estimatedLodScore":2.11,"family":{"id":"https://genegraph.clinicalgenome.org/r/6b402271-41f5-4b9e-90b9-399c082497fc","type":"Family","rdfs:label":"Family GK","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"}},"meetsInclusionCriteria":true,"phenotype":{"id":"obo:HP_0004904"},"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":7,"phenotypePositiveAllelePositive":8,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/e688200f-7fec-420e-a689-b1c9e5249a8f_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","rdfs:label":"Family R","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/e688200f-7fec-420e-a689-b1c9e5249a8f","type":"Family","rdfs:label":"Family R","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/92f652f7-98ee-447a-aa93-d9978dbbc4bc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","rdfs:label":"Family R-R6","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Linkage analysis using BAC, YAC, and PAC in the region of HNF1A on chromosome 12. Tested genes known in this region, exon trapping, and cDNA selection from pancreatic islets. Sequenced the 14 protein encoding genes in the region in addition to HNF1A. Sequenced all 10 exons in HNF1A.","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0004904","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/3407b7fc-ceb1-4a6e-a7cb-0cb8a3e4e266_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","allele":{"id":"https://genegraph.clinicalgenome.org/r/37f75bae-a7f6-41d9-8df7-a6cf13f04279","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000012.12:g.120996569_120996570del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658820837"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":5,"phenotypes":"obo:HP_0004904","proband":{"id":"https://genegraph.clinicalgenome.org/r/92f652f7-98ee-447a-aa93-d9978dbbc4bc"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/1917bc0f-b18f-4166-b2be-0c8975fd4b9a_family_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","rdfs:label":"Family P","estimatedLodScore":1.51,"family":{"id":"https://genegraph.clinicalgenome.org/r/1917bc0f-b18f-4166-b2be-0c8975fd4b9a","type":"Family","rdfs:label":"Family P","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"}},"meetsInclusionCriteria":true,"phenotype":{"id":"obo:HP_0004904"},"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":6,"phenotypePositiveAllelePositive":7,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/03fa992d-46b2-47fd-af2d-61f5bb39e726_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Glucksmann Families E, F, and G","family":{"id":"https://genegraph.clinicalgenome.org/r/03fa992d-46b2-47fd-af2d-61f5bb39e726","type":"Family","rdfs:label":"Glucksmann Families E, F, and G","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/5f577394-919c-4b08-b43d-1c0f0d678550","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"P291fs/Gly292Rfs Finn Founder","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Linkage analysis was performed across this family and 8 others) to determine the region responsible for MODY3. BAC and PAC constructioni was used to narrow the region of interest on chromosome 12q (markers D12S86 and D12S342). SSCP assays and sequence analysis were performed to identify the mutations in known and novel transcript. An additional 15 transcripts in the region were sequenced to negate their association with MODY3 disease.","phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypes":"obo:HP_0004904","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/2072f054-8a79-4284-93cc-3b17fe7dcbe8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","allele":{"id":"https://genegraph.clinicalgenome.org/r/970ad361-fd5c-4ac8-bde0-de66b2f7d2ac"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypePositiveAllelePositive":60,"phenotypes":"obo:HP_0004904","proband":{"id":"https://genegraph.clinicalgenome.org/r/5f577394-919c-4b08-b43d-1c0f0d678550"},"publishedLodScore":15.29},{"id":"https://genegraph.clinicalgenome.org/r/06ef5c5d-0ebc-4910-9053-684562397aa5_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","rdfs:label":"Edinburgh pedigree","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/06ef5c5d-0ebc-4910-9053-684562397aa5","type":"Family","rdfs:label":"Edinburgh pedigree","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/bd5c0c41-2fbd-4118-9cdd-af64611d9d68","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","rdfs:label":"Edinburgh-EA1","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Linkage analysis using BAC, YAC, and PAC in the region of HNF1A on chromosome 12. Tested genes known in this region, exon trapping, and cDNA selection from pancreatic islets. Sequenced the 14 protein encoding genes in the region in addition to HNF1A. Sequenced all 10 exons in HNF1A","firstTestingMethod":"Sanger sequencing","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f2b84b1b-56c0-4f1f-8dc2-d8a178eda857_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","allele":{"id":"https://genegraph.clinicalgenome.org/r/970ad361-fd5c-4ac8-bde0-de66b2f7d2ac"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":4,"phenotypePositiveAllelePositive":4,"phenotypes":"obo:HP_0004904","proband":{"id":"https://genegraph.clinicalgenome.org/r/bd5c0c41-2fbd-4118-9cdd-af64611d9d68"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/5093646a-327b-4208-b353-8888e21c734e_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","rdfs:label":"Family A","estimatedLodScore":2.11,"family":{"id":"https://genegraph.clinicalgenome.org/r/5093646a-327b-4208-b353-8888e21c734e","type":"Family","rdfs:label":"Family A","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/7554636a-20eb-4d48-9ab6-98cfa3c600f6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","rdfs:label":"Family A-A44","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Linkage analysis using BAC, YAC, and PAC in the region of HNF1A on chromosome 12. Tested genes known in this region, exon trapping, and cDNA selection from pancreatic islets. Sequenced the 14 protein encoding genes in the region in addition to HNF1A. Sequenced all 10 exons in HNF1A.","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0004904","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f9eceada-d4e2-4ff1-9988-4e1d0590f0e0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","allele":{"id":"https://genegraph.clinicalgenome.org/r/f1819b35-9378-4528-a65b-b86c7df5412d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000545.6(HNF1A):c.1340C>T (p.Pro447Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/14928"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":3,"phenotypePositiveAllelePositive":7,"phenotypes":"obo:HP_0004904","proband":{"id":"https://genegraph.clinicalgenome.org/r/7554636a-20eb-4d48-9ab6-98cfa3c600f6"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/075d433c-3f8c-4052-aa9a-3ba6c4651652_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Glucksmann-Family A","estimatedLodScore":1.51,"family":{"id":"https://genegraph.clinicalgenome.org/r/075d433c-3f8c-4052-aa9a-3ba6c4651652","type":"Family","rdfs:label":"Glucksmann-Family A","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/f5f229ea-3c98-4908-81f5-19304676321f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Glucksmann-Family A-IV:1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":20,"detectionMethod":"Linkage analysis was performed across this family and 8 others) to determine the region responsible for MODY3. BAC and PAC constructioni was used to narrow the region of interest on chromosome 12q (markers D12S86 and D12S342). SSCP assays and sequence analysis were performed to identify the mutations in known and novel transcript. An additional 15 transcripts in the region were sequenced to negate their association with MODY3 disease.","phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypes":"obo:HP_0004904","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/7752b783-5cc6-497a-b337-ebcb79d20688_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","allele":{"id":"https://genegraph.clinicalgenome.org/r/d35046f9-c843-4d69-88fd-cb95fd48f056","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000545.6(HNF1A):c.815G>A (p.Arg272His)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/14931"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypeNegativeAlleleNegative":8,"phenotypePositiveAllelePositive":6,"phenotypes":"obo:HP_0004904","proband":{"id":"https://genegraph.clinicalgenome.org/r/f5f229ea-3c98-4908-81f5-19304676321f"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/42237b09-11cd-495d-9d47-a340d70ee93d_proband_segregation","type":"FamilyCosegregation","dc:description":"The proband II:e was found to have a de novo mutation and passed it onto her son.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Glucksmann Family K","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/42237b09-11cd-495d-9d47-a340d70ee93d","type":"Family","rdfs:label":"Glucksmann Family K","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/ea6cc6ce-d94b-491f-9eac-046a718f2894","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Gluskmann Family K-II:e","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Linkage analysis was performed across this family and 8 others) to determine the region responsible for MODY3. BAC and PAC constructioni was used to narrow the region of interest on chromosome 12q (markers D12S86 and D12S342). SSCP assays and sequence analysis were performed to identify the mutations in known and novel transcript. An additional 15 transcripts in the region were sequenced to negate their association with MODY3 disease.","phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypes":"obo:HP_0004904","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/bcbe3b2e-847e-45ce-8512-3e0a98ecd45c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","allele":{"id":"https://genegraph.clinicalgenome.org/r/970ad361-fd5c-4ac8-bde0-de66b2f7d2ac"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypePositiveAllelePositive":2,"phenotypes":"obo:HP_0004904","proband":{"id":"https://genegraph.clinicalgenome.org/r/ea6cc6ce-d94b-491f-9eac-046a718f2894"}},{"id":"https://genegraph.clinicalgenome.org/r/7aa34a15-7aec-4070-a193-bc66ba86f957_proband_segregation","type":"FamilyCosegregation","dc:description":"Does not meet minimum requirements of 4 segregations for AD or X-linked inheritance.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","rdfs:label":"Family Ber","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/7aa34a15-7aec-4070-a193-bc66ba86f957","type":"Family","rdfs:label":"Family Ber","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/9a17ce41-3f7f-435b-9b7d-47e578fc3072","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","rdfs:label":"Family Ber-III:4,","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Linkage analysis using BAC, YAC, and PAC in the region of HNF1A on chromosome 12. Tested genes known in this region, exon trapping, and cDNA selection from pancreatic islets. Sequenced the 14 protein encoding genes in the region in addition to HNF1A. Sequenced all 10 exons in HNF1A.","firstTestingMethod":"Sanger sequencing","phenotypes":"obo:HP_0004904","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/01bcf10f-a510-4364-8afe-cdbbfaf4c48d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8945470","allele":{"id":"https://genegraph.clinicalgenome.org/r/9440a8e7-850d-4ea3-97f6-021f085bf25d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000012.12:g.120999500_120999501del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658820842"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":3,"phenotypePositiveAllelePositive":3,"phenotypes":"obo:HP_0004904","proband":{"id":"https://genegraph.clinicalgenome.org/r/9a17ce41-3f7f-435b-9b7d-47e578fc3072"}},{"id":"https://genegraph.clinicalgenome.org/r/3f172980-e5e2-424a-8d3f-0b690f1075d4_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Glucksmann-Family C","estimatedLodScore":3.61,"family":{"id":"https://genegraph.clinicalgenome.org/r/3f172980-e5e2-424a-8d3f-0b690f1075d4","type":"Family","rdfs:label":"Glucksmann-Family C","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/b0396e4f-9872-4870-9048-683fe149b1cd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Glucksmann Family C-III:1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":12,"detectionMethod":"Linkage analysis was performed across this family and 8 others) to determine the region responsible for MODY3. BAC and PAC constructioni was used to narrow the region of interest on chromosome 12q (markers D12S86 and D12S342). SSCP assays and sequence analysis were performed to identify the mutations in known and novel transcript. An additional 15 transcripts in the region were sequenced to negate their association with MODY3 disease.","phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypes":"obo:HP_0004904","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/73620cf6-be3f-4bea-ae96-0a9f211f8e8a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","allele":{"id":"https://genegraph.clinicalgenome.org/r/970ad361-fd5c-4ac8-bde0-de66b2f7d2ac"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypeNegativeAlleleNegative":4,"phenotypePositiveAllelePositive":12,"phenotypes":"obo:HP_0004904","proband":{"id":"https://genegraph.clinicalgenome.org/r/b0396e4f-9872-4870-9048-683fe149b1cd"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/01c5d3a6-f665-4866-92ab-ba1864cc8b82_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Glucksmann-Family D","estimatedLodScore":2.71,"family":{"id":"https://genegraph.clinicalgenome.org/r/01c5d3a6-f665-4866-92ab-ba1864cc8b82","type":"Family","rdfs:label":"Glucksmann-Family D","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/8362a0a1-7229-4288-a15d-e8a69000bc90","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Glucksmann-Family D-V:1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":15,"detectionMethod":"Linkage analysis was performed across this family and 8 others) to determine the region responsible for MODY3. BAC and PAC constructioni was used to narrow the region of interest on chromosome 12q (markers D12S86 and D12S342). SSCP assays and sequence analysis were performed to identify the mutations in known and novel transcript. An additional 15 transcripts in the region were sequenced to negate their association with MODY3 disease.","phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypes":"obo:HP_0004904","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/baae68f6-4a73-413a-a803-4907074e83a7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","allele":{"id":"https://genegraph.clinicalgenome.org/r/87b589ab-7723-47f8-9d2c-7edbec6bfe2f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000545.6(HNF1A):c.391C>T (p.Arg131Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/14943"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypeNegativeAlleleNegative":8,"phenotypePositiveAllelePositive":10,"phenotypes":"obo:HP_0004904","proband":{"id":"https://genegraph.clinicalgenome.org/r/8362a0a1-7229-4288-a15d-e8a69000bc90"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/71b6f856-e285-4dd3-ba24-20b244821a4c_proband_segregation","type":"FamilyCosegregation","dc:description":"Already included as part of glucksmann Families E, F, and GPreviously reported in Lehto et al., 1997 (PMID: 9045858) as Family A.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Glucksmann Family J","family":{"id":"https://genegraph.clinicalgenome.org/r/71b6f856-e285-4dd3-ba24-20b244821a4c","type":"Family","rdfs:label":"Glucksmann Family J","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/8a2c2d2b-77e2-4119-8d91-edbee6a21adc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","rdfs:label":"Glucksmann Family J-V:3","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":10,"detectionMethod":"Linkage analysis was performed across this family and 8 others) to determine the region responsible for MODY3. BAC and PAC constructioni was used to narrow the region of interest on chromosome 12q (markers D12S86 and D12S342). SSCP assays and sequence analysis were performed to identify the mutations in known and novel transcript. An additional 15 transcripts in the region were sequenced to negate their association with MODY3 disease.","phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypes":"obo:HP_0004904","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/884047b0-9896-44cf-9f73-3b996a6956ba_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9166684","allele":{"id":"https://genegraph.clinicalgenome.org/r/552485fd-ce88-4ba8-b082-5bbe66e1686e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000545.6(HNF1A):c.779C>T (p.Thr260Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/265436"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"All individuals in the study met diagnostic criteria for MODY including: (1) age of onset < 25 years, (2) correction of fasting hyperglycemia without insulin for at least 2 years, (3) nonketotic disease, (4) autosomal dominant mode of inheritance.","phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":7,"phenotypes":"obo:HP_0004904","proband":{"id":"https://genegraph.clinicalgenome.org/r/8a2c2d2b-77e2-4119-8d91-edbee6a21adc"},"publishedLodScore":15.29}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/2f6d71c6-6595-49bf-a50e-fce726b22088_ad_other_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f2b84b1b-56c0-4f1f-8dc2-d8a178eda857_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Vaxillaire et al., 1999  (PMID:10585422) performed some assays to look at changes to HNF1A protein function in the  P291fsinsC/ter (Gly292Argfs) mutant. Western lot analysis showed a truncated protein, deficient of the transactivation domain of HNF1A, which is responsible for its transcriptional activity (Figure 3A). Furthermore, that the P291ter/ G292Rfs was not able to activate transcription (Figure 5) compared to wildtype HNF1A, and showed that they inhibited the ability of wildtype co-transfected HNF1A to activate, indicating dominant negative function (Figure 6).  Given the evidence, it shows a mechanism consistent with loss of function, therefore I will increase the score to reflect a predicted null.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bd5c0c41-2fbd-4118-9cdd-af64611d9d68"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/884047b0-9896-44cf-9f73-3b996a6956ba_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The Thr260Met represent a hot spot mutation that has been reported upwards of 10 times (between published articles and variant databases) in individuals of differing ethnic backgrounds. there is some vidence to suggest through predicted algorithms that this mutation affects the DNA binding and thius activity of HF1A, as it is localized in a POU domain (Chi et al., 2002, PMID: 12453420). Furthermore, this mutation was shown to affect HNF1A function in bile synthesis in Ekholm et al. 2013, PMID: 23607861).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8a2c2d2b-77e2-4119-8d91-edbee6a21adc"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f9eceada-d4e2-4ff1-9988-4e1d0590f0e0_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant has shown to be a hotspot for mutation, as other individuals have the same and different variation at the site (Pro447) that have MODY. Vaxillaire et al., 1999 (PMID:10585422) performed some assays to look at changes to HNF1A protein function in the P447L mutant. They found that cells expressing the mutant P447L showed reduced expression of the construct by western blot (Figure 3A). The P447L mutant also had significantly reduced DNA binding capacity (Figure 3B). Furthermore, when they assessed the transcriptional activation of the P447L mutant compared to wildtype HNF1A they found almost no activation (Figure 5), and this mutant also shows a dominant negative activity, as it severely reduces the ability of co-transfected wildtype HNF1A to activate transcription (Figure 6C). This functional evidence supports a loss of protein function, thus I have increased the score to reflect the nature the mechanism.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7554636a-20eb-4d48-9ab6-98cfa3c600f6"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/73620cf6-be3f-4bea-ae96-0a9f211f8e8a_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Vaxillaire et al., 1999 (PMID:10585422) performed some assays to look at changes to HNF1A protein function in the P291fsinsC/ter (Gly292Argfs) mutant. Western lot analysis showed a truncated protein, deficient of the transactivation domain of HNF1A, which is responsible for its transcriptional activity (Figure 3A). Furthermore, that the P291ter/ G292Rfs was not able to activate transcription (Figure 5) compared to wildtype HNF1A, and showed that they inhibited the ability of wildtype co-transfected HNF1A to activate, indicating dominant negative function (Figure 6). Given the amount of evidence and showing a loss of protein function, I have increased the score.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b0396e4f-9872-4870-9048-683fe149b1cd"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/2072f054-8a79-4284-93cc-3b17fe7dcbe8_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Vaxillaire et al., 1999 (PMID:10585422) performed some assays to look at changes to HNF1A protein function in the P291fsinsC/ter (Gly292Argfs) mutant. Western lot analysis showed a truncated protein, deficient of the transactivation domain of HNF1A, which is responsible for its transcriptional activity (Figure 3A). Furthermore, that the P291ter/ G292Rfs was not able to activate transcription (Figure 5) compared to wildtype HNF1A, and showed that they inhibited the ability of wildtype co-transfected HNF1A to activate, indicating dominant negative function (Figure 6). Given the abundance of evidence to show loss of protein function, I have increased the score to maximum.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5f577394-919c-4b08-b43d-1c0f0d678550"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/31fd1ac3-398f-4d4d-8b2f-138f7a8ef370_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Vaxillaire et al., 1999 (PMID:10585422) performed some assays to look at changes to HNF1A protein function in the P291fsinsC/ter (Gly292Argfs) mutant. Western lot analysis showed a truncated protein, deficient of the transactivation domain of HNF1A, which is responsible for its transcriptional activity (Figure 3A). Furthermore, that the P291ter/ G292Rfs was not able to activate transcription (Figure 5) compared to wildtype HNF1A, and showed that they inhibited the ability of wildtype co-transfected HNF1A to activate, indicating dominant negative function (Figure 6). Given the variant evidence shows loss of protein function, I have increased the score to reflect this mechanism.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97b4e6d2-d0ae-4ad9-9730-e51d9180d698"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/7752b783-5cc6-497a-b337-ebcb79d20688_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The R272H variant has been observed several times in unrelated individuals diagnosed with MODY, indicating a mutational hotspot (PMIDs 9313763, 11463573, 19150152, 9032114, etc). Vaxillaire et al, 1999 (PMID:10585422) performed some assays to look at changs to HNF1A protein function when the R272 is mutated to H (R272H). they found that the R272H mutant HNF1A construct was unable to stably bind DNA compared to wildtype transfected a R272H construct into CC3 cells to look at cellular localization and ability of the mutant HNF1A to bind DNA. They found that the R272H construct had a slighlty reduced ability to bind DNA compared to wildtype HNF1A (Figure 3B). they also concluded that the R272H mutant had reduced intrinsic transactivation, which was most likely a result of the reduced capacity to bind DNA. Upgraded points to reflect that this mutation results in a loss of protein function.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f5f229ea-3c98-4908-81f5-19304676321f"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/dae43e13-96f3-4f5d-940f-517f49d801cb_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Per Chi et al., 2002 (PMID:12453420) the Leu107Arg (L107R) mutation may perturb protein stability as it is located in the Palpha1 region that binds and stabilizes the POU domain. The Leu107 is a highly mutable sight and other variants have been reported at this region (L107I and L107V) with MODY(Lehto, et al., 1999; Lindgren, et al., 2002, (Bellanne-Chantelot, et al., 2008, Klupa, et al., 2002). Per Cervin, et al., 2002 (PMID: 12488960), the L107I causes educed DNA binding and reduction in transactivation (~50%), suggsting that perturbation of this site results in changes to HNF1A function.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b6adbb0a-e676-44bc-aa3b-442ccee4f0f8"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/baae68f6-4a73-413a-a803-4907074e83a7_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Per BjÃ¸rkhaug et al., 2003 (PMID: 12574234) the R131W mutation showed impaired nuclear localization, impaired DNA binding, and reduced transactivation(~43% percent of wildtype). Given that the evidence shows loss of protein function, I have increased the score to reflect this mechanism.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8362a0a1-7229-4288-a15d-e8a69000bc90"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/4f3e8aa2-1a0a-466c-b3ec-7c51dbf9bda2_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Down scored as no variant evidence to support changes in HNF1A function or pathogenicity.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fee0c6ef-c9c5-4b2e-a0dc-826d920114a5"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityOverallAutosomalDominantOtherVariantEvidenceCriteria","strengthScore":7},{"id":"https://genegraph.clinicalgenome.org/r/2f6d71c6-6595-49bf-a50e-fce726b22088_ad_null_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/01bcf10f-a510-4364-8afe-cdbbfaf4c48d_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9a17ce41-3f7f-435b-9b7d-47e578fc3072"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/3407b7fc-ceb1-4a6e-a7cb-0cb8a3e4e266_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/92f652f7-98ee-447a-aa93-d9978dbbc4bc"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallAutosomalDominantNullVariantEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/2f6d71c6-6595-49bf-a50e-fce726b22088_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bcbe3b2e-847e-45ce-8512-3e0a98ecd45c_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant as shown to occur de novo in the proud, to which she passed onto her son. Furthermore, the pro bands parents were negative for the mutation, although they both developed T2D in old age (64 yo for father and 76 yo for the mother). Haplotype analysis indicated that the mutation occurred de novo on the maternal allele and thus the analysis also confirmed maternity and paternity. Therefore I have increased the score to maximum.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ea6cc6ce-d94b-491f-9eac-046a718f2894"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/2f6d71c6-6595-49bf-a50e-fce726b22088_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2f6d71c6-6595-49bf-a50e-fce726b22088_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b4f338c7-e8e5-4171-9e52-17fec998f1a8","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b362833e-acc2-4f58-bbbf-afa7d34a67fa","type":"Finding","dc:description":"NCBI gene evidence from HPA RNA-seq of normal tissues show the highest expression of HNF1A in the kidney, duodenum, small intestine, liver, colon, and pancreas. The pancreas, liver, and kidney have all been implicated in the MODY phenotype.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24309898","rdfs:label":"HNF1A RNA expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ad04bf93-2f6c-4157-91fd-2225d1387e68","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd73261a-1cdf-4e41-b8ef-d7b08e2190e8","type":"Finding","dc:description":"In vitro synthesized HNF1A and HNF4 were generated in E.coli cells, by standard procedures. The HNF1A was labelled with 35S-methoinine, to aid in identification of these molecule for the binding assay. HNF4A was tagged with GST (glutathione transferase), again to aid in the indetification and pull down of this molecule.The HNF4A proteins generated contained amino acids 130-368 (and lacked the nuclear localization signal to aid in the interation assay), HNF4A AF2 domain alone, and HNF4A (130-368) with the AF2 domain deleted (deltaAF2) were tagged with GST and produced in E.coli. Equal amounts of tagged HNF1A and each of the HNF4A isoforms were incubated separately, along with GST beads to bind the molecules, in a physiological buffer and incubated for 4 hours. The reactions were washed extensively, and the beads were resuspended in reducing buffer (containing SDS) and analyzed by SDS-PAGE. The 35-S labelled HNF1A was probed on the gel, and indicated that HNF1A could bind the HNF4A (130-368), and the HNF4A -AF2 domain alone, but was unable to bind the HNF4A deleted of the AF2 domain (Figure 5A).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9204893","rdfs:label":"HNF1A interacts with the AF2 domain of HNF4A","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/22b0237e-0417-42b9-9a5f-e02c54e330a3","type":"EvidenceLine","dc:description":"The co-regulation of pancreatic and hepatic genes by HNF1A and HNF4A has been repeated in several independent articles and labs. Furthermore, HNF1A and HNF4A have been shown to regulate each genes expression, implicating them in a feedback regulatory loop. Therefore, I will increase the points to 1.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c365de65-1fd6-4298-bb39-ce163f0e1ebe","type":"Finding","dc:description":"Both HNF1A and HNF4A are transcription factors that regulate genes responsible for glucose metabolism, insulin secretion, and lipid metabolism.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14988562","rdfs:label":"HNF1A regulates pancreatic genes as does HNF4A","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/2f6d71c6-6595-49bf-a50e-fce726b22088_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8448757b-549c-4190-9faf-e1f2e1d44190","type":"EvidenceLine","dc:description":"The rescue was achieved by tetracycline control of  HNF1A expression in a spatiotemporal manner, and showed recess of gene transcritption. However, the mice still exhibited a diabetes phenotype due to the issue of some cells within the mouse still having altered HNF1A expression (either knockout or over expression due to the tetracycline control). Therefore, I have reduced the points for this rescue to 0.5 points.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c132e885-ce92-4b74-a80c-82bbd32aeebd","type":"Finding","dc:description":"Transcription of genes known to be regulated by HNF1A and potentially contribute to the MODY phenotype, including Fxr, Glut2, Dbp, Hgd2, HNF4A, Hgfa, and Pklr, were shown to be regulated within ranges of wildtype when HNF1A was re-expressed in the beta islets of HNF1A null mice.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16873682","rdfs:label":"HNF1A rescue  in Beta-islets rescues gene transcription","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d1d78aae-5b52-47bc-a766-8e197c4ceef3","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1567a47f-8085-4aec-aeee-a67b46ffe65c","type":"Finding","dc:description":"Transgenic male mice showed development of diabetes around 6 weeks of age, corresponding with maturation towards reproduction age. Females showed glucose intolerance at 3 months of age, but remained normo-glycemic up to 15 months old (figure 1). Immunostaining of beta-cells at 10 weeks old (in males and females) showed reduced numbers of beta-calls compared to wildtype littermates (Figure 2).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11713231","rdfs:label":"Dominant negative HNF1A mice develop diabetes","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/07d167ec-2a09-45df-a51b-9994bf96b0f5","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/400d2b9c-370c-4bc0-949f-40a2021c955d","type":"Finding","dc:description":"Evidence provided specifically in Lee et al., 1998, PMID: 9566924. The HNF1A null mice were born at less than half of the expected Mendelian ratio, indicating intrauterine death. the neonates were noted as being smaller than their wildtype or heterozygous littermates (figure 2). At 12 weeks of age the HNF1A null mice showed significantly lower weights than control littermates. The livers of the HNF1A mice were ~50% larger than control littermates, and further, these mice showed altered levels of liver enzymes AST (aspartate aminotransferase ) and ALT (alanine aminotransferase). The HNF1A null mice developed hyperglycemia 2 weeks after birth, and blood glucose levesl remained low thereafter. At 6 weeks olf, the HNF1A null mice showed 330X higher glucose in urine than control littermates, indicating diabetes (figure 3C, and D, and Table 2).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16873682","rdfs:label":"HNF1A null mice develop diabetes","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":1935,"specifiedBy":"GeneValidityCriteria6","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/_4M_MyqfzNk","type":"GeneValidityProposition","disease":"obo:MONDO_0015967","gene":"hgnc:11621","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_2f6d71c6-6595-49bf-a50e-fce726b22088-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}